Who was studied, and how
Four numbers in the abstract
Where each one falls
Where it lands on the map
493people with type 2 diabetes, in this paper
Among high baseline glucagon, the trial randomly assignedassigned by chance
acarbose
acarbose (low glucagon subgroup)
Reported lower HbA1c reductions, no range given−1.32
randomisedAmong medium baseline glucagon, the trial randomly assignedassigned by chance
acarbose
acarbose (low glucagon subgroup)
Reported lower HbA1c reductions, no range given−1.27
randomisedthe abstract, start to end
… greater HbA1c reductions at 24 weeks (-1.32 % for high and -1.27 % for medium vs. -0.87 % for low; both P < 0.05) and at 48 weeks (-1.23 % for high and -1.30 % for medium vs. -0.79 % for …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
HbA1c reductionsacarbose vs acarbose (low glucagon subgroup), in high baseline glucagon
−1.32
HbA1c reductionsacarbose vs acarbose (low glucagon subgroup), in medium baseline glucagon
−1.27
HbA1c reductionsacarbose vs acarbose (low glucagon subgroup), in high baseline glucagon
−1.23
HbA1c reductionsacarbose vs acarbose (low glucagon subgroup), in medium baseline glucagon
−1.30
Other glucose-loweringGlycemic control
1 / 4